Felora

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Felora

Property Description
Active Ingredient Diclofenac (e.g., sodium, potassium salt)
Form Tablets, capsules, gels, solutions, injections
Pharmacological Class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common Use Relief of pain, inflammation, and fever
Origin Synthetic (Phenylacetic acid derivative)

What Type of Medicine is Felora?

Felora is a synthetic Nonsteroidal Anti-Inflammatory Drug (NSAID), a pharmacological classification that is clinically recognized for its anti-inflammatory, analgesic, and antipyretic actions. The medicine's identity is defined by its active ingredient, Diclofenac, which belongs to the distinct phenylacetic acid class. Diclofenac is a benzene-acetic acid derivative that stands out within the broader NSAID group due to pharmacological studies suggesting it is a partially selective inhibitor of the COX-2 enzyme, setting it apart from non-selective alternatives. The mechanism of NSAIDs confirms this action is foundational for reducing the swelling and pain associated with inflammation.

What is the Composition of Felora?

The composition of the medication is based on the potent active constituent, Diclofenac, often presented as a salt to optimize absorption, and is typically a single-component product. Felora is available across various dosage form(s) to suit different needs, including forms designed for systemic absorption, such as various tablets and capsules, as well as highly specialized forms for targeted delivery, such as topical gels and transdermal patches. This versatility allows for administration via the oral, topical, or parenteral route(s).

What is the General Purpose of Felora?

The general purpose of Felora is to provide foundational relief from the common and concurrent symptoms of inflammation, widespread pain, and elevated fever. By acting to interrupt the synthesis of prostaglandins, the chemical mediators central to these physical responses, the drug serves to manage general discomfort caused by inflammatory signaling. Its effectiveness is well-documented in clinical practice for scenarios requiring symptomatic relief of general pain and swelling, making it a globally recognized component of symptomatic management. The Diclofenac molecule is recognized as an established, non-narcotic way to help ease mild to moderate discomfort and swelling.

What side effects are possible with Felora?

Possible Side Effects and Safety Information

The information below outlines the officially documented safety profile for Felora, structured according to mandatory government regulatory classifications. This summary is based strictly on data presented in authoritative regulatory documents from agencies such as the FDA, EMA, and NIH, and is intended to communicate risk based on reported clinical trial and post-marketing experience.

Adverse Reaction Scope

Adverse reactions associated with Felora are systematically categorized based on the frequency with which they occurred in clinical trials (e.g., Very Common, Common, Uncommon) and by the System-Organ Class (SOC)—the specific body system they affect (e.g., Gastrointestinal Disorders, Nervous System Disorders). This framework allows for a clear, incidence-based view of the medicine’s risk profile.

Serious Adverse Reactions (SARs): Regulatory documents define serious adverse reactions as those that are life-threatening, result in significant disability, require hospitalization, or lead to death. These reactions, and the conditions for which the drug is strictly Contraindicated (must not be used), are clearly highlighted as they represent the most critical safety information.

Population-Specific Safety: The regulatory safety profile addresses specific patient groups where the risk-benefit assessment may differ, including use in pediatric patients, geriatric patients, and individuals with underlying conditions such as impaired kidney or liver function. Specific monitoring or cautions are defined for these populations.

Dose and Exposure-Related Patterns: Information may be included regarding adverse reactions that occur more frequently, or with greater severity, with higher doses or prolonged courses of treatment, which helps to define the risk context of use.

Regulatory Safety Summary

  • The official safety profile provides a formal, evidence-based communication of risk, distinct from anecdotal reports.
  • All reported adverse effects are systematically grouped by both frequency and the body system affected to ensure a comprehensive mapping of potential health risks.
  • The most critical risks are established through the formal listing of serious adverse reactions and conditions that make the medicine strictly unsuitable for use (contraindications).
  • Specific safety notes are defined in official documents regarding the need for monitoring certain laboratory parameters or observing precautions during the product’s use.

The overall safety structure ensures that the magnitude and nature of all documented risks are clearly defined, setting the official boundaries for the medicine's safe use across different patient populations.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose is a medical emergency that can be fatal and requires immediate attention.

Felora, as a potent opioid, carries a significant risk of severe, life-threatening overdose primarily characterized by respiratory depression. This is a dangerous slowing or stopping of breathing, which can lead to profound sedation, coma, and death. Because of substantial differences in how Felora is absorbed compared to other fentanyl products, substitution or incorrect dosing can result in a fatal overdose.

Signs of Overdose

If you or someone you are caring for experiences any of the following signs, seek emergency medical help immediately:

  • Slow, shallow, or difficult breathing (hypoventilation).
  • Severe sleepiness or profound sedation.
  • Inability to wake up or respond (unresponsiveness).
  • Cold, clammy skin or blue/purplish lips and fingernails.

Immediate Emergency Action

  • Call 911 (or your local emergency number) immediately. State that you suspect an opioid overdose.
  • Administer an opioid overdose reversal agent (such as naloxone) if one is available. Naloxone can rapidly reverse the effects of the opioid but may require multiple doses, especially with potent opioids. Follow the instructions for the reversal agent, and continue monitoring the person.
  • All patients and caregivers should be counseled on having a reversal agent available due to the significant risk of accidental and potentially fatal overdose, particularly in children or individuals who are not opioid-tolerant. The risk of overdose is also increased by using Felora with other Central Nervous System depressants (like alcohol or benzodiazepines) or with CYP3A4 inhibitors.

Therapeutic Uses of Felora

What Felora Treats: Main Uses and Benefits

Felora is applied across domains where additional symptomatic support is needed, providing support that helps ease the overall symptom burden of acute and chronic discomfort. In clinical practice, the medication is commonly used to help with symptoms related to arthritis, acute pain, and other inflammatory conditions.

Therapeutic Scope and Support

The medication may be relevant in clinical settings marked by persistent joint inflammation or sudden onset discomfort. Felora is commonly used across conditions presenting with systemic or localized discomfort, such as Rheumatoid Arthritis, Osteoarthritis, and Ankylosing Spondylitis. It is commonly used in situations involving recurrent or episodic manifestations, such as Primary Dysmenorrhea (menstrual pain), Migraine attacks, and elevated body temperature (fever).

It is used for managing symptom clusters that may become intense or disruptive, including joint pain, stiffness, and swelling. For patients managing these manifestations, the relief offered contributes to easing the overall symptom load and may assist with maintaining functional stability.


Quick Fact: Relief for Inflammatory Pain

Felora is a supportive agent relevant when supportive symptom management is appropriate for symptoms related to inflammatory or irritative states.

Regulatory References

  1. NIH MedlinePlus overview of Diclofenac

Eligibility and Restrictions for Use

This section outlines the official population eligibility and non-eligibility for Felora, strictly based on authoritative government regulatory documentation.

Who Must Not Use Felora (Contraindications)

The medicine is formally contraindicated and must not be used by patients with a known hypersensitivity to the active substance (Felora) or any of its excipients. Absolute contraindications also apply to individuals with specific, severe, uncompensated organ failure (e.g., acute liver failure) where the drug’s use poses an unacceptable risk, as defined in the label.

Use in Specific Populations (Restrictions and Limitations)

Population Group Regulatory Status/Restriction
Pediatric Patients (Under 18) Safety and efficacy not established; use is not recommended or prohibited.
Pregnant/Lactating Females Use is not recommended during pregnancy or lactation due to documented fetal/infant risk or excretion in breast milk.
Severe Organ Impairment Patients with severe renal or hepatic impairment are restricted from use or require conditional caution, often necessitating a specific dose modification not detailed here.

Eligibility is generally limited to adult patients who do not have any of these officially documented exclusionary criteria or comorbidities.

What should I know about interactions with other medicines?

Felora Interactions with Other Medicines and Products

This section outlines the officially documented interaction patterns for Felora (Diclofenac) as described in government regulatory sources, such as the FDA and national medicines agencies. These interactions relate to co-administration with other medicines, products, or specific clinical conditions.


Official Interaction Classifications and Restrictions

Classification Interacting Entity or Condition Regulatory Statement
Contraindicated Coronary Artery Bypass Graft (CABG) Surgery Prohibited in the setting of CABG surgery.
Not Recommended Aspirin (Analgesic Doses) or Other NSAIDs Increases the risk of serious gastrointestinal events.
Exposure Modifying Voriconazole (CYP Inhibitor) Documented to increase Diclofenac's plasma exposure (AUC and Cmax).

Documented Pharmacodynamic and Pharmacokinetic Effects

Co-administration with Felora may result in changes to how other medicines work or how they are handled by the body:

  • Anticoagulants and Antiplatelets: Increases the risk of serious bleeding and gastrointestinal events.
  • Antihypertensives (ACE Inhibitors, ARBs) and Diuretics: May reduce the blood pressure-lowering or fluid-eliminating effects of these medicines.
  • Narrow Therapeutic Index Drugs: Felora can increase the serum concentrations of co-administered Lithium and Digoxin.

Population-Specific Cautions

The concomitant use of Felora with ACE Inhibitors or ARBs in the elderly, those who are volume depleted, or patients with renal impairment may lead to deterioration of kidney function, as stated in official labeling.

Mechanism of Action

Felora's mechanism is driven by molecular interactions that modulate key physiological cascades, resulting in defined systemic consequences. Its primary action is the reversible inhibition of Cyclooxygenase (COX) enzymes, specifically the inducible COX-2 enzyme, which is synthesized at sites of tissue stress. By halting the COX-2-mediated conversion of arachidonic acid into pro-inflammatory PGE2, the drug modifies an early molecular step that shapes downstream physiological events.

The reduction in PGE2 concentration affects two core systems. Peripherally, it reduces the chemical sensitization of peripheral nerve endings (nociceptors), which are critical for transmitting afferent signals, leading to a physiological adjustment in nociceptive signaling dynamics. Centrally, the inhibition of prostaglandin synthesis in the hypothalamus removes the chemical signal that dictates an elevated body temperature setpoint, thereby leading to the restoration of the thermoregulatory setpoint and affecting central thermoregulation.

Dosage and Administration Information

How to Use Felora: Administration Guidelines

This guidance reflects the specific administration instructions and constraints that are documented in the prescribing information for this medication.

Administration Scope Official Instruction
Route of Administration Oral use only.
Dosing Schedule Once daily (q.d.) regimen for adults.
Standard Adult Dose 200 mg.
Timing in Relation to Meals May be taken without regard to food.
Preparation Requirements Film-Coated Tablets must be swallowed whole; do not split, crush, or chew.
Dose Modification Required for patients with moderate renal impairment (CrCl 30–50 mL/min), for whom the dosage is reduced to 100 mg once daily.
Missed Dose Rule If a dose is missed, administer it as soon as the omission is identified. If it is close to the time for the next scheduled dose, omit the missed dose and resume the regular daily schedule. Do not take two doses on the same day.

Administration Protocol

  1. Take the prescribed dosage strength (100 mg or 200 mg) one time every 24 hours.
  2. Administer the dose by mouth, swallowing the entire tablet with water.
  3. Maintain consistency by taking the medicine at approximately the same time each day.

This information details the procedural steps and dose constraints for using the product, ensuring compliance with the documented protocol for drug administration.

Recent Clinical Evidence

Research evidence / Overview of Studies for Felora

This overview summarizes the available research and clinical trials conducted on Felora (Diclofenac), describing the study types, the outcomes that were measured, and the aspects that remain uncertain, strictly based on official and peer-reviewed scientific sources.


Evidence for Use in Osteoarthritis

The evidence exploring how symptoms change over time for Osteoarthritis (OA) is based on short- and mid-term Randomized Controlled Trials (RCTs) and supporting systematic reviews. These studies were designed to measure changes in outcomes related to physical discomfort and daily functioning or activity level in adult populations. Researchers examined patient-reported outcomes describing perceived discomfort, such as measures of pain intensity, joint stiffness, and scores related to daily activities, across various oral and topical formulations.

Studies monitored how symptoms changed in the observed populations over defined time intervals. The research describes short-term changes in these symptomatic outcomes, contributing to the broader evidence landscape. However, follow-up durations were limited, meaning that long-term outcomes regarding sustained functional changes are not fully established.


Evidence for Use in Inflammatory Rheumatic Conditions

Felora was evaluated in research contexts involving fluctuating or unstable symptoms for conditions such as Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS). Research explored the use of the medicine during periods of heightened symptom activity, typically lasting up to a year. Outcomes linked to inflammatory or irritative states were monitored, including measurements of joint tenderness, joint swelling, and patient- and physician-reported global assessments of disease activity.

Studies report that outcomes related to physical discomfort and joint inflammation were observed in some studies. The research primarily describes outcomes related to symptomatic relief, and it is not yet clear whether the medicine affects the long-term course of RA or AS. Comparative evidence against other therapeutic classes is not widely documented in the foundational evidence base.


What Remains Uncertain and Research Gaps

Overall, the research highlights what is known—and what is still uncertain—about Felora. The main limitations found across the evidence base include: Follow-up durations were limited in many key trials; Evidence quality varies across studies due to the different formulations and doses; and Subgroup findings are uncertain for specific patient groups defined by rare comorbidities or advanced disease states.

Key Studies & References

  1. Label: DICLOFENAC SODIUM tablet, delayed release (FDA/DailyMed)
  2. Treatment Efficacy of Celecoxib and Diclofenac Sodium in Rheumatoid Arthritis: A Review
  3. Diclofenac: new contraindications and warnings (Government Safety Update)

Frequently Asked Questions (FAQ)

Common questions about Felora (FAQ)


Q: Is Felora safe to use during pregnancy or while breastfeeding?

A: Official product information states that using Felora is not usually recommended during pregnancy, especially in the later stages, due to documented potential risks of harm to the fetus. When breastfeeding, only tiny amounts may pass into breast milk. The potential use during pregnancy or lactation is a topic for discussion with a healthcare provider.


Q: What are the most serious, but less common, risks associated with Felora?

A: Official documents highlight an increased risk of serious cardiovascular thrombotic events, which include heart attack or stroke, and serious gastrointestinal (GI) events, such as bleeding or ulcers in the stomach and intestines. Additionally, severe liver injury and certain rare skin reactions are listed as critical safety information based on regulatory data.


Q: Why is Felora not recommended for people with a history of heart problems?

A: Regulatory findings associate Felora with an increased risk of serious arterial thrombotic events, which are dangerous blood clots. Official guidance indicates it is contraindicated (must not be used) in patients with established heart conditions like heart failure, ischaemic heart disease, or cerebrovascular disease.


Q: Do I need to take Felora forever?

A: The continuation of Felora use is subject to periodic re-evaluation by a healthcare professional. Official guidance states that the lowest effective dose for the shortest duration possible should be used. This approach is intended to manage symptoms while minimizing potential cardiovascular risks.


Q: How long does it usually take to feel the effects of Felora?

A: Felora is generally absorbed quickly after being taken by mouth, with peak concentrations typically reached in about two hours in individuals who are fasting. However, the exact time it takes to feel symptomatic relief can depend on the specific formulation being used and the condition being treated.


Q: What happens if I forget to use Felora one time?

A: If a dose is missed and it is very close to the time for your next scheduled dose, the regulatory rule suggests omitting the missed dose and sticking to the regular schedule. Official warnings caution users against taking two doses on the same day.


Q: Is it common to feel tired when first starting Felora?

A: Official safety data lists excessive tiredness (fatigue) and a lack of energy as reported side effects. Regulatory documents mention that unusual weakness or tiredness can be a symptom of anemia, a condition noted in the safety profile.


Q: Are there certain foods or drinks I should avoid while using Felora?

A: Official warnings strongly advise patients to limit alcoholic beverages while using Felora. This is because combining the medicine with alcohol may significantly increase the risk of serious gastrointestinal problems, such as bleeding and ulcers.


Q: Can Felora affect my sleep?

A: Official safety documents list both insomnia (difficulty falling or staying asleep) and, conversely, somnolence (drowsiness) as possible adverse reactions. This indicates that the medicine may have an effect on a user's normal sleep patterns.


Q: Is it normal if I have a headache after starting Felora?

A: Yes, headache is included in the official safety information as a reported side effect of Felora (Diclofenac). If headaches are severe or do not resolve, this may warrant discussion with a healthcare provider.


Q: Is Felora safe for older adults (seniors)?

A: Official product labeling states that older adults are at a greater risk for experiencing serious adverse events, particularly those affecting the stomach, intestines, and kidneys. Official labeling notes that use in older adults requires careful monitoring by a professional and often involves the use of the lowest effective dose for the shortest duration.


Q: What does the research say about the long-term use of Felora?

A: Regulatory warnings indicate that the risks of serious cardiovascular events and serious gastrointestinal events may increase when Felora is taken over a long period. The official product documents recommend using the drug for the shortest possible duration to manage symptoms.


Q: Why do official documents state that Felora is only for specific uses?

A: Official indications reflect that Felora has been formally studied and approved by regulatory authorities only for the treatment of specific conditions, such as the relief of pain, inflammation, and symptoms related to certain types of arthritis. Regulatory approval is limited to these defined uses.


Q: Do I need a special blood test before I can start using Felora?

A: Official documents advise that healthcare providers may recommend periodic monitoring of kidney function, liver function, and blood counts if the medicine is taken long-term. A mandatory blood test before starting treatment is not specified for all patients, but specific requirements are based on individual clinical circumstances.


Q: Is it true that Felora can cause changes in weight?

A: Official safety information lists unexplained weight gain as a serious side effect for which users are advised to seek professional attention. This symptom may be related to fluid retention (edema), which is also a reported adverse reaction.


Q: Does Felora interact with oral contraceptives (birth control pills)?

A: Regulatory guidance suggests that Felora is not expected to affect the effectiveness of hormonal contraceptives, including both the combined oral pill and the progestogen-only pill.


Q: Why does the packaging for Felora have a specific warning about a certain group of people?

A: Regulatory agencies require warnings (like the Boxed Warning in the US) to draw immediate attention to serious or frequently occurring risks identified during the drug's development or post-marketing use. This ensures users are aware of critical risks, such as the increased potential for cardiovascular and gastrointestinal events.


Q: Is it normal to feel a bit dizzy in the first week of using Felora?

A: Dizziness is listed in the official safety information as a reported adverse reaction of Felora (Diclofenac). Dizziness is a side effect that may affect a patient's ability to concentrate, according to official information.


Q: Is there a maximum time someone can be on Felora?

A: Official guidance emphasizes that the medicine should be taken for the shortest duration possible to manage symptoms. This is because the risks of serious adverse events, particularly cardiovascular and gastrointestinal risks, may increase with the length of time the drug is used.


Q: Are there any specific lifestyle changes recommended when using Felora?

A: Users are advised to limit alcoholic beverages to reduce the risk of gastrointestinal complications. Additionally, the label may advise caution regarding sun exposure as some medicines in this class can increase sensitivity to sunlight.


Q: Can I take Felora if I have high blood pressure?

A: Official documents warn that Felora can cause the new onset of hypertension (high blood pressure) or worsen existing high blood pressure. Blood pressure should be monitored closely during treatment, and the medicine may reduce the effectiveness of blood pressure-lowering medications.


Q: Does Felora have a risk of dependence or addiction?

A: Felora (Diclofenac) is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID) and is not a narcotic. Official regulatory documents indicate that there is no reported risk of dependence or addiction associated with its use.


Q: Are there any requirements about driving or operating machinery while on Felora?

A: Because the medicine can cause side effects such as dizziness or drowsiness, patients are advised to exercise caution. If side effects like dizziness or drowsiness occur, caution is warranted regarding driving or operating machinery, as stated in the patient counseling information.


Q: Do all patients experience side effects from Felora?

A: No. Official safety documents categorize adverse reactions based on their frequency in clinical trials (e.g., Common, Uncommon). This indicates that most reactions are only experienced by a minority of users, meaning not all patients will experience side effects.


Q: What makes Felora suitable for the condition it treats?

A: Felora's suitability is based on its core pharmacological action: the ability to inhibit the body's synthesis of prostaglandins. These are the chemical mediators that are central to the processes of pain, inflammation, and fever, aligning with the drug's approved indications for symptomatic relief.


Q: Can I stop using Felora suddenly?

A: Official guidance for those using Felora long-term states that treatment should be re-evaluated periodically by a healthcare provider. The decision to discontinue the medication is a subject for discussion with the prescribing professional, especially for long-term users.


Q: Does Felora change how my liver functions?

A: Yes, Felora can cause elevations in liver enzymes, which may be detected through lab tests. In rare circumstances, serious and potentially fatal liver injury (hepatotoxicity) has been reported. Regular monitoring of liver function tests may be recommended during use.


Q: How quickly is Felora eliminated from the body?

A: Felora (Diclofenac) is eliminated relatively quickly. According to official pharmacokinetic data, the terminal phase of elimination has a half-life of approximately 2 hours. This short half-life means the concentration of the medicine typically declines rapidly after peak levels.


Q: Is there a time of day that is better for using Felora?

A: Administration guidelines state that the medicine should be taken at approximately the same time each day to maintain a consistent level in the body. Official documents do not specify a universally better time (such as morning or night) for all patients.


Q: Is the benefit of Felora sustained over a long period?

A: Clinical evidence is mostly derived from short- to mid-term studies. The official research summary indicates that long-term outcomes regarding sustained functional changes are not fully established, and the continued need for symptomatic relief should be regularly assessed by a professional.

How should Felora be stored and disposed of?

How to Store and Dispose of Felora: Official Regulatory Requirements

The storage and disposal instructions for Felora are derived exclusively from regulatory labeling and documentation. These requirements ensure the medicine maintains its stability and effectiveness until its expiration date.

Storage Requirement Official Guidance
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C.
Protection Protect from moisture and excessive heat. Do not freeze.
Packaging Keep the medicine in its original, tightly closed container.

For stability and handling, the medicine must be kept in its sealed container and away from children's reach. Disposal of unused or expired Felora should follow authorized guidelines. This includes utilizing local medication take-back programs or following government-specified household disposal procedures to prevent environmental contamination, strictly avoiding flushing down the toilet or pouring into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Felora found in:

A-Z Index: